BenevolentAI gets $115M to harness AI for new drug discovery

BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States. Existing backer Woodford Investment Management also participated in the round, which brings the company ’s total funds raised to over $200 million.
Source: mobihealthnews - Category: Information Technology Source Type: news